ProCE Banner Activity

Final Prespecified OS Analysis of PROpel: Phase III Trial of First-line Abiraterone + Olaparib vs Abiraterone + Placebo in Metastatic CRPC

Capsule Summary
Conference Coverage

First-line abiraterone plus olaparib showed a median OS of approximately 42 months, the longest yet reported in a phase III trial in first-line mCRPC.

Released: February 22, 2023

Expiration: February 21, 2024

Begin Activity


Provided by

ProCE Banner


Supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.